To the full analysis
Novozymes stock: growth
NSIS-B.CONovozymes reported $4.6B in revenue for fiscal 2025, up 8.5% on the prior year, down 21.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
−2.6%
per year from 2006 to 2025, per share −4%
Earnings (Annual rate)
8.6%
per year from 2006 to 2025, per share 6.3%
Free cash flow (Annual rate)
9.3%
per year from 2006 to 2025, per share 7.7%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | −21.6% | −11.4% | −2.6% |
| Revenue per share | −27.5% | −14.1% | −4.0% |
| Earnings | −27.1% | −14.6% | 8.6% |
| Earnings per share | −34.1% | −18.1% | 6.3% |
| Free cash flow | −26.1% | −10.9% | 9.3% |
| Free cash flow per share | −31.7% | −13.5% | 7.7% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $7.54B | $134.96M | $152.89M |
| 2007 | $1.1B | $155.56M | $144.3M |
| 2008 | $9.03B | $1.18B | $109.82M |
| 2009 | $9.36B | $177.63M | $118.69M |
| 2010 | $10.78B | $1.79B | $147.89M |
| 2011 | $1.56B | $271.86M | $206.67M |
| 2012 | $12.45B | $2.23B | $234.04M |
| 2013 | $13.02B | $2.44B | $2.04B |
| 2014 | $13.81B | $2.8B | $4.24B |
| 2015 | $15.52B | $3.13B | $2.63B |
| 2016 | $15.67B | $3.38B | $3.06B |
| 2017 | $16.1B | $3.46B | $2.74B |
| 2018 | $15.95B | $3.57B | $2.6B |
| 2019 | $15.93B | $3.49B | $2.59B |
| 2020 | $15.53B | $3.13B | $3.78B |
| 2021 | $2.23B | $468.73M | $3.13B |
| 2022 | $2.61B | $546.69M | $1.24B |
| 2023 | $19.83B | $3.35B | $2.32B |
| 2024 | $4.24B | $338.59M | $731.46M |
| 2025 | $4.6B | $646.2M | $831.85M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = DKK 6.7461, $1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Jul 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.